NCT00038454暂停2 期
A Phase II, Randomized, Single-Blind, Controlled Clinical Trial to Evaluate the Efficacy and Safety of Hemolink[Tm] (o-Raffinose Cross-Linked Human Hemoglobin) in Subjects Undergoing Primary Coronary Artery Bypass Grafting Surgery
Hemosol55 个研究点 分布在 3 个国家目标入组 180 人开始时间: 2002年5月31日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 暂停
- 发起方
- 入组人数
- 180
- 试验地点
- 55
研究概览
简要总结
To evaluate the efficacy of Hemolink™ in combination with Intraoperative Autologous Donation (IAD) versus control (IAD alone) in facilitating avoidance of allogeneic RBC transfusion during and following primary CABG surgery
详细描述
All subjects who consent to take part in the protocol and who meet the inclusion/exclusion criteria will undergo the IAD harvest following a post-induction IAD harvest calculation. IAD blood will be collected into citrate-phosphate-dextrose-adenine 1 (CPDA-1) blood bags. All subjects will receive a volume of Hespan® equal to the volume of their IAD harvest (to a maximum of 1 liter) performed as a result of the harvest calculation (0-1200 mL inclusive). Additional volume replacement required owing to IAD >1000mL will be performed with crystalloid, as required. Subjects will be randomized into one of two treatment arms (Hemolink™ arm or control arm) upon meeting a transfusion trigger for the first time while on CPB. Randomization will be administered centrally. Subjects will be transfused upon reaching predetermined transfusion triggers, reflecting a decrease in hemoglobin concentration and/or oxygenation:
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Single
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects meeting all of the following criteria are eligible for inclusion in the study:
- •Written Informed Consent.
- •Age 18 through 80 years, inclusive.
- •Scheduled for primary CABG surgery with CPB and are candidates for IAD.
- •Post-induction hemoglobin, which will allow collection of 0-1200 mL inclusive of IAD blood to achieve a target hemoglobin of 7.5 g/dL at 15 minutes on-CPB.
- •For women of childbearing potential only, able to use and using a highly-effective contraceptive method from the time of study screening through week 4 - 8 post CABG surgery (follow-up visit).
- •Note: International Conference on Harmonization (ICH) guidelines define a highly-effective contraceptive method as one with a failure rate of less than one percent when used consistently and correctly
排除标准
- •Subjects meeting any of the following criteria will be excluded from the study:
- •Previous treatment with Hemolink(tm) or any other hemoglobin-based oxygen carrier.
- •Participation in any clinical trial of an investigational drug, device, or medical procedure within the two months prior to enrollment, or concurrent with participation in this study.
- •History of stroke with residual paralysis or of transient ischemic attacks within 6 months prior to surgery.
- •Congenital coagulation disorder or treatment with Coumadin within seven days prior to surgery.
- •Alcohol or drug use within the 12 months prior to enrollment, which the investigator considers abusive.
- •Planned simultaneous surgery (e.g., valve repair or carotid endarterectomy).
- •Emergency CABG.
- •Previous surgery using sternotomy.
- •Current pregnancy or nursing.
- •Chronic pancreatitis with or without pancreatic insufficiency.
- •Any subject who is medically cleared for both the surgical procedure and the intraoperative autologous donation will be eligible for enrollment in the study.
- •Medical clearance requires the following:
- •No current congestive heart failure, New York Heart Association class IV.
- •Most recent (within 1 year of surgery) ejection fraction must not be less than or equal to 25 percent, or left ventricular function of grade
- •No current uncontrolled hypertension.
- •No current severe pulmonary disease which will render the subject at high risk of requiring prolonged post-operative ventilation.
- •No serum creatinine > 2.0 mg/dL (177 umol/L).
- •No known AST and ALT and bilirubin > 3 times the upper limit of normal.
- •No uncontrolled angina within 24 hours prior to surgery despite maximal medical treatment, and/or presence of an intraaortic balloon pump preoperatively.
- •No history of transmural myocardial infarction within the five days prior to the scheduled CABG surgery.
研究者
研究点 (55)
Loading locations...
相似试验
暂停
1 期
Phase I/II Clinical Trial Stem Cell Gene Therapy in RAG1-Deficient SCIDSevere Combined Immunodeficiency Due to RAG1 DeficiencyNCT04797260Videja B.V.10
招募中
1 期
ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM)Multiple MyelomaNCT05632380Institute of Hematology & Blood Diseases Hospital, China20
招募中
1 期
Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same DonorSIODSLE NephritisCKD Stage 4FSGSCystinosisNCT05508009Alice Bertaina12
招募中
2 期
Allo HSCT Using RIC and PTCy for Hematological DiseasesAcute Myelogenous LeukemiaAcute Lymphocytic LeukemiaBiphenotypic Acute LeukemiaUndifferentiated LeukemiaMyelodysplastic SyndromesLeukemia, MyeloidMyelodysplastic Syndrome With Excess Blasts-1Burkitt LymphomaRelapsed T-Cell LymphomaRelapsed Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaMarginal Zone LymphomaMyeloproliferative NeoplasmProlymphocytic LeukemiaChronic Myelogenous LeukemiaFollicular LymphomaMyelofibrosisPlasma Cell LeukemiaNCT05805605Masonic Cancer Center, University of Minnesota56
终止
2 期
Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202)Recurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaFollicular LymphomaNCT00096460Medical College of Wisconsin30